Basic information Safety Supplier Related

Umeclidinium bromide

Basic information Safety Supplier Related

Umeclidinium bromide Basic information

Product Name:
Umeclidinium bromide
Synonyms:
  • DIPHENYL-[1-(2-PHENYLMETHOXYETHYL)-1-AZONIABICYCLO[2.2.2]OCTAN-4-YL]METHANOL;BROMIDE
  • CS-1562
  • Umeclidinium bromide(GSK573719A)
  • 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide
  • Umeclinidium bromide
  • GSK573719A;GSK-573719A;GSK 573719A
  • 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide
  • GSK573719A
CAS:
869113-09-7
MF:
C29H34BrNO2
MW:
508.48976
EINECS:
638-761-1
Product Categories:
  • API
  • 869113-09-7
Mol File:
869113-09-7.mol
More
Less

Umeclidinium bromide Chemical Properties

Melting point:
>231°C (dec.)
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly), Water (Slightly)
form 
Solid
color 
White to Off-White
Stability:
Hygroscopic
More
Less

Umeclidinium bromide Usage And Synthesis

Description

Umeclidinium bromide is a long-acting muscarinic acetylcholine antagonist developed by GlaxoSmithKline and approved by the US FDA at the end of 2013 for use in combination with vilanterol, a b2 agonist, for the treatment of chronic obstructive pulmonary disease. Due to umeclidinium’s poor oral bioavailability, the drug is administrated by inhalation as dry powder.

Uses

Umeclidinium Bromide is considered as a potentially long-acting antimuscarinic agent.

Definition

ChEBI: A quaternary ammonium salt that is the bromide salt of umeclidinium. Used in combination with vilanterol for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Synthesis

Commercially available ethyl isonipecotate (278) was alkylated with 1-bromo-2-chloroethane in the presence of K2CO3 in acetone to give ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (279). This material was then treated with lithium diisopropylamine (LDA) in THF to affect a transannular substitution reaction resulting in the cyclized quinuclidine 280 in 96% yield. Excess of phenyllithium was added to ester 280 in THF starting at low temperature then gradually warming to room temperature to give tertiary alcohol 281 in 61% yield. Amine 281 was finally alkylated with benzyl 2- bromoethyl ether (282) in MeCN/CHCl3 at elevated temperatures to afford umeclidinium bromide (XXXV) in 69% yield.

References

[1] salmon m, luttmann m a, foley j j, et al. pharmacological characterization of gsk573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. journal of pharmacology and experimental therapeutics, 2013, 345(2): 260-270.

Umeclidinium bromideSupplier

Anhui Dexinjia Biopharm Co., Ltd Gold
Tel
0531-82375887 13596650888
Email
3385307203@qq.com
Bono Kangyuan (Beijing) Pharmaceutical Technology Co., Ltd Gold
Tel
010-56380788-8515 16619769925
Email
wch013@bionna.cn
Shanghai Goyic Pharmaceutical & Chemical Co., Ltd. Gold
Tel
021-50689757 15618953996
Email
sales@goyic.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
BeiJing Hwrk Chemicals Limted
Tel
0757-86329057 18934348241
Email
sales4.gd@hwrkchemical.com
More
Less

Umeclidinium bromide(869113-09-7)Related Product Information